Abstract
Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and / or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligandreceptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.
Keywords: Diphtheria Fusion Protein Therapy, Chemoresistant Malignancies, Pseudomonas exotoxin, saporin, gelonin, diphtheria toxin, genetically engineered diphtheria toxin, cancer therapy, corynebacterium diphtheriae, iymphocytic leukemia cll
Current Cancer Drug Targets
Title: Diphtheria Fusion Protein Therapy of Chemoresistant Malignancies
Volume: 2 Issue: 1
Author(s): Arthur E. Frankel, Patrick Rossi, Timothy M. Kuzel and Francine Foss
Affiliation:
Keywords: Diphtheria Fusion Protein Therapy, Chemoresistant Malignancies, Pseudomonas exotoxin, saporin, gelonin, diphtheria toxin, genetically engineered diphtheria toxin, cancer therapy, corynebacterium diphtheriae, iymphocytic leukemia cll
Abstract: Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and / or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligandreceptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.
Export Options
About this article
Cite this article as:
Frankel E. Arthur, Rossi Patrick, Kuzel M. Timothy and Foss Francine, Diphtheria Fusion Protein Therapy of Chemoresistant Malignancies, Current Cancer Drug Targets 2002; 2 (1) . https://dx.doi.org/10.2174/1568009023333944
DOI https://dx.doi.org/10.2174/1568009023333944 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Molecular Docking of New Thiophene Derivatives as Lactate Dehydrogenase-A Inhibitors
Mini-Reviews in Medicinal Chemistry Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism
MicroRNA Current Strategies for Probing Substrate Specificity of Proteases
Current Medicinal Chemistry New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers Macrocyclic Compounds: Emerging Opportunities for Current Drug Discovery
Current Pharmaceutical Design Cell-Specific Induction of Apoptosis by Rationally Designed Bivalent Aptamer-siRNA Transcripts Silencing Eukaryotic Elongation Factor 2
Current Cancer Drug Targets Research Progress of Exogenous Plant MiRNAs in Cross-Kingdom Regulation
Current Bioinformatics Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Targeting Signaling Pathways in Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Respiratory Medicine Reviews Molecular Determinants of Enzyme Cold Adaptation: Comparative Structural and Computational Studies of Cold- and Warm-Adapted Enzymes
Current Protein & Peptide Science Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Medicinal Chemistry Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Fabrication and Evaluation of Colon Targeted Uricase Containing Microbeads for Treatment of Gout
Drug Delivery Letters Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Interrelationships between Hepatic Fat and Insulin Resistance in Non- Alcoholic Fatty Liver Disease
Current Diabetes Reviews Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets